Obesity
Obesity
Addressing Obesity
For over 15 years, Schaeffer researchers have examined obesity’s consequences for government budgets, including Medicare and Social Security, the impact it has on individuals’ health outcomes, and the value of new interventions and treatments.
Related Topics
Top Stories View All
Comment Letters
Comments to CMS on Proposed Medicare and Medicaid Coverage of Anti-Obesity Medications
Featured Experts: Dana Goldman, Bryan Tysinger, Alison Sexton Ward
In The News View All
Medscape
Medicare coverage of obesity drugs could presure other insurers to follow suit, Ward says
Featured Experts: Alison Sexton Ward
USC Today
Obesity and diabetes drugs can catalyze profound changes in your body — and in public health, too
Featured Experts: Darius Lakdawalla, Anne Peters, Christopher Scannell
Oprah Daily
Qato discusses disparities in GLP-1 coverage
Featured Experts: Dima M. Qato
STAT
Medicare Should Cover Wegovy — but Not Negotiate Its Price
Featured Experts: Joseph Grogan
Yahoo Finance
Medicare coverage of GLP-1s could make doctors more accepting of the drugs, Goldman says
Featured Experts: Dana Goldman
Featured White Paper
Benefits of Medicare Coverage for Weight Loss Drugs
The cumulative social benefits from Medicare coverage for new obesity treatments over the next 10 years would reach almost $1 trillion, or roughly $100 billion per year.
Experts: Alison Sexton Ward, Bryan Tysinger, PhuongGiang Nguyen, Dana Goldman, Darius Lakdawalla
Scholar Testimony
Testimony on Incentivizing Chronic Disease Prevention and Treatment
Rebalancing the healthcare system to favor prevention and cures can potentially reduce the long-term burden of obesity and other chronic diseases, Senior Scholar Anne Peters testified before the House Ways and Means health subcommittee.
Read the Testimony
